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Chapter 1 







Dynamic combinatorial chemistry (DCC) is a powerful tool to identify bioactive 
compounds. This efficient technique allows the target to select its own binders 
and circumvents the need for synthesis and biochemical evaluation of all 
individual derivatives. An ever-increasing number of publications report the 
use of DCC on biologically relevant targets. The work here complements reviews 
by focusing on the experimental protocol and giving detailed examples of 
essential steps and factors that need to be considered, such as protein stability, 
buffer composition and cosolvents. 
 
 
This chapter has been published as a review article: 
A. M. Hartman, R. M. Gierse, A. K. H. Hirsch, Eur. J. Org. Chem. 2019, 3581–
3590. 
A. M. Hartman and R. M. Gierse contributed equally to the work in this chapter. 
 
Section 1.4 was taken from the submitted review article: 
P. Kirsch, A. M. Hartman, A. K. H. Hirsch, M. Empting,  






Since its dawn more than two decades ago, combinatorial chemistry 
approaches[1–5] have developed into target-directed dynamic combinatorial 
chemistry (tdDCC) and have matured as a hit- identification tool. There has been 
an increasing number of work published in this niche of supramolecular 
chemistry.[6–11] A growing number of groups have shown the general applicability 
and scope of tdDCC for the identification of modulators of targets.[6,12–20] tdDCC 
refers to general pharmacologically relevant targets which next to proteins also 
include DNA and RNA, whereas protein-templated DCC (ptDCC) only refers to 
proteins. Several reviews and book chapters on tdDCC have been published in 
recent years.[21–23] This chapter covers our work on ptDCC and provides the key 
features of our protocol, explaining the essential steps in designing a successful 
ptDCC experiment.  
Carefully chosen building blocks are connected in a reversible manner via 
covalent or noncovalent bonds to form a dynamic combinatorial library (DCL) 
(Figure 1). Biocompatibility, pH dependence, temperature, solubility and stability 
of the components are important factors, which should be taken into account. The 
ideal DCLs do not require cosolvents, however, it can occur that the formed 
products have a lower solubility than the building blocks and in order to keep all 
compounds in solution, a cosolvent such as dimethyl sulfoxide (DMSO) is 
commonly used. Precipitation of DCL components could lead to an undesired 
shift in the equilibrium. By contrast, a desired shift of the equilibrium can be 
obtained by the addition of an external stimulus, such as a protein target. There 
are in general two different approaches that can be followed in ptDCC: ‘adaptive 
DCC’, in which the target is present during the formation of the DCL and ‘pre-
equilibrated DCC’, in which the target is added after the DCL is established. An 
advantage of pre-equilibrated DCC is that the exchange chemistry can be applied 
in conditions which are not tolerated by the protein. A disadvantage is that the 
screening step is performed under static conditions and no amplification effects 










In ptDCC, the member(s) of DCLs, which bind best will be amplified, leading to 
an increase in their concentration compared to a control reaction without the 
external stimulus. These binders can then be further evaluated for their 
biochemical properties. 
To enable a comparative analysis of DCLs, a blank reaction, without the target, 
should be run concurrent with a templated reaction. Another approach of DCC is 
non-comparative, in which the hits can be analysed in complex with the target or 
after being released from the target. There are different techniques that can be 
used to analyse the DCLs: liquid and size-exclusion chromatography coupled to 
mass spectrometry, NMR spectroscopy, fluorescence spectroscopy and X-ray 
crystallography. Figure 2 illustrates the comparative approach versus the non-
comparative approach, which can be adopted in DCC. The reaction mixture can 
be ‘frozen’, in order to prevent the library from re-equilibrating during the 
analysis. In the case of acylhydrazone chemistry, this can be achieved by an 
increase in pH. Denaturation by heat, addition of a solvent or (ultra-fast) 













Figure 2. DCC approaches: comparative and non-comparative. In the comparative 
approach the library in presence of a target is compared to the library in absence of the 
target. In the non-comparative approaches, the hit–target complexes will be separated 
from the mixture and analysed as a complex or as released hits. The figure was adapted 




1.1.1 Reversible reactions suitable for DCC 
Only a limited number of reversible reactions have been used thus far, they are 
summarised in Scheme 1. One of the most frequently used reactions is the 
(acyl-)hydrazone formation, which combines ketone or aldehyde building blocks 
with (acyl-)hydrazides. This condensation reaction can take place in water, 
making it biocompatible.[24] The synthesis of the building blocks is generally 
straightforward or they may be commercially available. 
At physiological conditions, neutral pH and room temperature, acylhydrazone 
formation and exchange are relatively slow. At acidic pH, the equilibrium is 
reached rapidly. However, Greaney and coworkers have shown that the pH 
dependence can be influenced by the addition of a nucleophilic catalyst. They 
were able to reach equilibrium reasonably fast at a comparatively high pH of 6.2 
by using aniline, as a nucleophilic catalyst.[12] Previously Dawson and coworkers 
have shown that aniline could serve as a catalyst for acylhydrazone formation and 
oxime ligation.[25,26] Derivatives of aniline, which bear substituents at the aryl 
ring, are even more effective catalysts.[27]  
The acylhydrazone linkage is reversible under acidic conditions and stable against 
hydrolysis at physiological pH values, allowing for the ‘freezing’ of the reversible 











Scheme 1. Reversible reactions used in target-directed DCC to identify bioactive 







Scheme 1 continued. Reversible reactions used in target-directed DCC to identify 
bioactive compounds. Scheme was adapted from Van der Vlag and Hirsch.[23] 
An overview of studies published over the past five years in the field of ptDCC is 
given in Table 1. It must be noted that much more work has been published 
applying DCC for the formation of diverse libraries in the drug-discovery process. 
For example the coupling of DCC to DNA-encoded libraries, creating so called 
DNA-encoded dynamic combinatorial chemical libraries (EDCCLs). Iminobiotin 
and homotetrameric streptavidin were used as a model system to identify a 
bidentate protein/ligand interaction. The addition of an external stimulus, for 
example a target protein, can shift the thermodynamic equilibrium and hence a 
DNA amplification can be observed after sequencing.[28] 
Table 1. Protein-templated DCC studies reported over the past five years, in which a target 
was used as a template to influence the equilibrium. Therefore, only articles using an 
adaptive approach are listed, pre-equilibrated DCC examples are omitted.[29–31] The table 











Best affinity Ref. 
Wt Tau RNA Disulfide HPLC-MS 
and NMR 
21 2 days Fluorescence 
titration 
EC50 = 70 nM [32] 





Imine HRMS 297 24 h In vitro activity 
against cancer 
cell lines 
IC50 = 2.4 µM [34] 
Endothiapepsin Acylhydraz
one 
HPLC-MS 90 20 h Inhibition assay IC50 = 54.5 nM 









HPLC 11 24 h Fluorescence-
based assay and 
MIC 
KD = 3 µM 












n.a. in vivo activity 
assay 





19F-NMR 5 12 h Enzymatic 
assay 












10 5 h HPLC-based 
demethylase 
and DSF assays 














DSF = differential scanning fluorimetry, HPLC = high-performance liquid 
chromatography, IC50 = half maximal inhibitory concentration, ITC = isothermal titration 
calorimetry, KD = dissociation constant, Ki = inhibition constant, MIC = minimum 
inhibitory concentration, MS = mass spectrometry, n.a. = not available, NMR = nuclear 
magnetic resonance, SPR = surface plasmon resonance, Tm = thermal shift. 
1.2 A closer look on the templating protein 
To obtain meaningful results from DCC experiments, the quality of the input 
template is critical. As the equilibrium of the library shifts by the templating effect 
of the added protein sample, it should consist of the target protein as close to its 
native state as possible. The quantity of the used template depends on the protein 
target, there are reported successful DCC projects with 0.1 to 1.5 equivalents of 
protein. [29,42] DCC experiments are also possible with a mixture of proteins, but 
a well-defined sample eases up downstream data analysis and reduces the 
number of false positives for the desired target.[40] The condition of the protein 
sample depends on various variables. For DCC experiments the purity, 
concentration, tertiary and quaternary structure of the protein, additives and 
contaminations, as well as the pH-value are of particular importance. During the 
experiment, which can take up to several days, protein degradation and 
precipitation could occur. The tests described herein should give an overview and 
help to choose suitable experimental conditions to plan new DCC experiments. In 
the next paragraphs, we will briefly discuss the influence of those factors and 
suitable analytical methods to monitor them. 
1.2.1 Purity 
In the case of a mixed or impure protein sample, there might be several templated 
reactions proceeding in parallel. It is impossible to differentiate between a small 




protein pool showing only a weak amplification of a binder. This will result in 
overlapping data, which are difficult to analyse, and may result in false positives. 
We therefore recommend starting with the highest protein purity available. 
1.2.2 Stability 
Not only the initial state, but also the stability of the templating protein during 
the reaction should be checked by preliminary tests before conducting a DCC 
experiment. The time span over which a DCC experiment, pre-equilibrated or 
adaptive, is monitored can vary. It depends on the reaction rate and 
concentration and should ideally be monitored until the library reaches an 
equilibrium state. Usually, the DCL reaches a new equilibrium within the first few 
days, depending on the reversible reaction and conditions (Table 1). However, if 
the protein is stable for longer periods of time, longer equilibration times are 
possible, for example up to 20 days for the very stable protease endothiapepsin 
(see Section 1.2.4).[24] 
It is important that the protein is not precipitating or degrading during the 
experiment. Precipitation of the protein will remove the template from the 
solution. Denaturation of the template will lead to entirely new templates, which 
would affect the equilibrium state of the DCL. This can lead to random and 
irreproducible amplification of compounds by the unordered protein and a 
decrease of initially already amplified best binders of the native template. If the 
protein target is labile, it is therefore necessary to follow the reaction over time to 
identify the temporary, templated equilibrium of the DCC library. In this, 
compounds amplified by the native state of the template can be found.  
Eventually, after prolonged incubation time, nearly every protein will degrade 
and, by this, change the equilibrium of the DCL again. Compounds amplified in 
this step can be ignored, as they were not templated by the native protein. 
Observation of the DCC experiment for longer timeframes than the template 
integrity can be guaranteed is therefore of no use.    
1.2.3 Buffer and pH 
When choosing a buffer for DCC experiments, several different requirements 
have to be met. Attention should be paid to possible side reactions with the DCL 
or chelation effects. For example, Tris-buffer could form imines with aldehyde 
building blocks, which might influence the formation of the DCL. Some 
stabilization of the protein is beneficial, but strong interactions of the buffer with 
the target protein should also be avoided, for instance, a phosphate buffer for a 
phosphate binding protein. The phosphate could compete with possible binders; 
possible effects of competition are discussed in more detail in Section 1.2.5.  So 




Table 2 and Scheme 2. The choice of buffer is, however, not limited to the 






Scheme 2. Example of possible buffers and the pH ranges of reactions used in DCC 
experiments. 
 
Table 2. Buffers commonly used in different DCC reactions. *Tris buffer requires special 
attention. 
Reaction Buffer described in literature 
Acylhydrazone formation [6,24,36] Ammonium- and Sodium acetate, Phosphate, Tris* 
Hydrazone formation [43,44] Phosphate, Tris*  
Disulfide [45,46] Phosphate, Borate 
Thioether [47] Water/DMSO 
Imine [13] Water 
Boronate ester [14,48] Ammonium acetate, Water 
 
For many protein targets, the stability at room temperature and the optimal 
buffer conditions are not known. We therefore recommend determining these 
conditions prior to performing DCC experiments. As several interdependent 
factors, like pH, buffer, ionic strength and ions influence the stability of a protein, 
it is difficult to suggest a stepwise flow scheme for the determination of the ideal 
buffer composition for a given protein.[28] Not only the protein but also the 
exchange chemistry might be affected significantly by varying these parameters. 




range in parallel. Afterwards, a small selection (2 to 5) of the most stabilizing 
combinations can be evaluated for their long-term effect on the protein. 
Subsequently, the best condition will then be used to determine the influence of 
DMSO (Section 2.6) and, if of interest, additives (Section 2.5). The selection of 
the initial buffers could be broadened, in case no suitable condition was found. 
Two or more buffers should be screened per pH value to distinguish the influence 
of the buffer component and the pH value on the stability of the protein. It is also 
possible to use a so-called “superbuffer”,[49] a mix of three or more buffer 
components, enabling the adjustment of a wide pH-range, without changing the 
buffer composition or concentration. 
The effect of the buffer components on a protein can be measured in a 
straightforward way, by determining the melting point of the target protein via a 
thermal-shift assay / differential scanning fluorimetry (TSA /DSF).[28] In this 
method, the protein is incubated together with a lipophilic dye, for example sypro 
orange. The dye shows an increase in fluorescence after binding to the 
hydrophobic parts of a protein. These are often located at the inside of a protein 
and become exposed during temperature-induced unfolding/melting. The 
temperature–dependent increase in fluorescence can be measured in a RT-PCR 
apparatus and yields the Tm of the protein. 
Other methods, like DSC, ITC and CD (differential scanning calorimetry, 
isothermal titration calorimetry and circular dichroism spectroscopy) and the 
determination of melting points by CD could also be used to gain information on 
the interaction and possible stabilization of the protein with its buffer, but require 
a high amount of protein and/or long measurement time. The TSA, however, 
offers high throughput and a short assay time, together with already several 
published or commercially available kits in 96-well format.[50,51] These kits were 
originally intended to screen for optimal crystallization conditions and cover 
several stability-influencing conditions. When performing DCC experiments, the 
design of an individual 96-well plate layout, tailored to the buffers and conditions 
compatible with the planned DCC reaction, might be useful. This is a short time 
investment, which might pay off quickly in the future, if ptDCC is used on several 
different targets. 
After a DCC–compatible, stabilizing buffer condition has been identified, the 
protein should be checked for its long-term stability. To check for cleavage of the 
protein backbone an analysis by SDS-PAGE is of sufficient sensitivity (Figure 3). 
To determine if the protein folding is affected, TSA is again the method of choice, 
since the signal directly depends on the unfolding process of the protein. With 
prolonged degradation, the melting point decreases slightly. As a secondary effect 




points and an overall decrease in signal intensity and resolution. A fully 
denatured enzyme will just show a decreasing fluorescence signal with no peak 
from protein unfolding. As controls, a fresh and a heat-treated sample of the 
target protein should be included in the experiment.  
The tendency of a protein to precipitate is concentration-dependent. Because of 
this, the assays determining the protein stability should be performed with the 
same protein concentration that is intended to be used in the DCC experiment. If 
this is not possible, due to limited protein availability, the first experiments might 
be done with less protein. However, at least for the chosen final condition, the 
stability assessment should be repeated with the protein concentration that will 











Figure 3. 12% SDS-PAGE of different homologues of the enzyme 5-Deoxyxylulose 
5-Phosphate Synthase (DXS) after incubation at RT. The protein on the upper gel shows 
no sign of degradation. The second protein, shown on the lower gel, shows signs of 
degradation, starting already at day one with a very faint band around 50 kDa. From day 
6 on a decrease of the main protein band also becomes clear. In the top left corner a gel-






1.2.4 Functional enzyme assay 
For enzymatic protein targets, a functional assay can be used instead of TSA and 
PAGE measurements for the assessment of long-term stability. The analysis of 
activity data of a functional assay to determine the best experimental conditions 
of the DCC experiments leaves less room for interpretation than the analysis of 
the results of a melting-point analysis. Therefore, if a functional assay is available, 
and the enzyme is showing catalytic activity in the desired pH range of the DCC 
reaction, the activity assay should be the method of choice.   
In a previous study from 2014, we could monitor the activity of the target protein 
endothiapepsin by performing a fluorescence-based assay (Figure 4). The pH-
optimum of endothiapepsin is 4.5, and the enzymatic activity was not affected 
even after 20 days incubation at RT and a pH of 4.6. Considering this high 







1.2.5 Additives and contaminations 
During the purification, the protein might be in contact with different buffers and 
conditions. Some of the buffer components might remain bound to the protein, 
even after a buffer exchange. These contaminants might influence the 
experiment. It is therefore recommended to critically evaluate the composition of 
the protein sample. Not only should the protein storage buffer be evaluated, but 
also the origin of the sample. 
Common substances that could be found in protein samples are for example 
imidazole as a leftover from an IMAC (immobilised metal affinity 
chromatography) purification step. Protein samples are often supplemented with 
reducing agents like 2-ME, DTT or TCEP (2-Mercaptoethanol, Dithiothreitol or 
Tris(2-carboxyethyl)phosphine) in concentrations up to 10 mM to keep the 
Figure 4. Activity of endothiapepsin, a pepsin-like aspartic protease, in a fluorescence-
based assay at different time intervals of incubation at room temperature. Figure was 




protein in a reducing environment. If disulfide formation is the reversible 
reaction of choice, the final reducing agent concentration should be evaluated to 
make sure that the formation of disulfide bonds is not inhibited.  
The effect of additives and contaminations is related to the volume of the protein 
sample used in the individual DCC experiments. This not only determines the 
final concentration of protein, but also the concentrations of the contaminants. If 
the batch-to-batch concentration of the protein varies and its volume is adjusted 
to reach the same final concentration in the DCC experiment, it should be noted 
that the concentrations and effects of the additives in the DCC experiment might 
vary. 
Compounds that remain in the protein sample can have an influence on the DCC 
reaction or on the target protein. One should critically check every buffer 
component on possible interference with the planned exchange chemistry. 
Screening literature for known reactions between the DCL members and sample 
components can be considered. Performing a control experiment with all buffer 
components, in the absence of protein, can assure that no side reactions are 
taking place. If the exact composition of the protein sample is unknown, a small 
volume of the buffer might be gained by concentration of the protein using an 
ultrafiltration device and using the flow-through for the control experiment.  
Some agents used during protein purification, such as cryoprotectants like 
glycerol or detergents like Tween, will interact in a non-specific way with the 
protein surface. From our experience, if there is no hint that they might affect the 
experiment, leftover cryoprotectants and detergents can be tolerated. Special care 
should be taken if cofactors, coenzymes or ions are supplemented during the 
purification process to stabilise the enzyme. The same holds true for buffer 
components structurally related to those supplements. Everything that binds to 
the targeted binding pocket is competing with the DCC library. If a natural, tight 
binding cofactor is present during the experiment, it could prevent the building 
blocks from binding and therefore also inhibit their amplification. However, the 
use of tight binders can be beneficial in control experiments. If a compound with 
a known binding site is inhibiting the formation of some previously observed 
binders this can be taken as a hint that the templated binders are targeting the 
same protein pocket. 
1.2.6 DMSO 
Addition of a small percentage of DMSO to the reaction solution is a common 
practice in the design of enzymatic assays to improve the solubility of 
hydrophobic compounds. For biochemical assays, DMSO concentrations up to 




In DCC experiments, the building blocks of the library are typically dissolved in 
DMSO stock solutions to enable the easy assembly of a library. Depending on the 
library composition and number of compounds used, the final DMSO 
concentration would vary. To keep the reaction conditions comparable, we 
recommend adding DMSO up to a concentration that can be kept constant for all 
experiments of a project. This fixed concentration should be evaluated and 
chosen beforehand, to ensure the protein tolerates it.  
DMSO has a very broad range of effects on proteins, it can even decrease the 
solubility and induce precipitation.[53] Both, rate acceleration, as well as 
inhibition of the enzyme-catalysed reaction by DMSO have been observed. An 
influence of already low percentages of DMSO on the enzymatic activity often 
hints to DMSO acting as an unspecific effector, interacting with the active site of 
the enzyme.[54] If the enzymatic activity is reduced by DMSO at higher 
concentrations (>10% DMSO ), it is often by influencing the overall protein 
conformation by displacing water molecules bound to the surface and unfolding 
the protein.[55] On the other hand, there are  DMSO-tolerant enzymes known 
which show activity up to 80% DMSO.[54] Enzyme activity assays are the method 
of choice to estimate the effect of DMSO on an enzyme. If no activity assay is 
available, the effect of DMSO could also be measured using TSA, however, 
interactions with the active site are difficult to detect with this method. We often 
observe a small effect on the Tm of a protein, but a strong effect on the enzymatic 
activity. Taken together, the DMSO concentration has several effects on the 
protein structure. The benefits of DMSO addition need to be weighed against the 
risk of creating an artificial enzymatic fold, which could amplify compounds that 
would not bind under native conditions. Therefore, the DMSO concentration 
should be as low as possible, in our lab up to 5% are regularly used. 
1.2.7 Temperature 
To speed up the rate at which the DCL reaches equilibrium, the experiments are 
normally performed at room temperature. For labile proteins, a lower reaction 
temperature may be necessary, which can improve the stability of the proteins. 
At the same time, the equilibration rate is decreased, leading to a prolonged 
incubation time. The optimal temperature for protein stability in DCC could vary 
from enzyme to enzyme and thus needs to be evaluated in each individual case 
but room temperature is used in most cases.  
1.3 Setting up a ptDCC experiment 
When crystal structures are available, or even cocrystal structures, a structure-
based approach can be undertaken to design promising building blocks. In this 
case also non-binders could be designed as control elements, which are not 




selected because it influences the molecular recognition by the target. For 
example, the acylhydrazone linkage resembles the amide functionality; and 
features hydrogen-bond donors and acceptors. We showed that by combining 
DCC with de novo structure-based design, the risks associated with this attractive 
approach are reduced.[24] 
1.3.1 Formation of the DCLs 
The building blocks might have to be dissolved in DMSO, allowing them as well 
as the formed products to stay soluble in the final mixture. In principle, they could 
also be dissolved in the desired buffer, which would be most ideal. In 2014, we 
coupled DCC to saturation-transfer difference (STD)-NMR spectroscopy, which 
requires lower concentrations of protein than a general DCC experiment (Table 
3). STD-NMR spectroscopy enables selection of the binders from the DCL, since 
the intensity of these signals is stronger due to a more efficient saturation 
transfer. As a result of only observing binders, STD-NMR spectra cannot be used 
to determine concentrations of DCL members and therefore amplification cannot 
be calculated. In follow-up experiments, it is possible to determine the KD value 
of a ligand via STD-NMR or other biophysical assays.[56] 
The ratio of hydrazides versus aldehydes should allow for the formation of all 
possible products, therefore at least one equivalent of each hydrazide per 
aldehyde should be used. For example, if three aldehydes are used then at least 
three equivalents of each hydrazide should be added, making sure that there is an 
excess of hydrazides. When required, a nucleophilic catalyst like aniline could be 
added. The most frequently used concentration of DMSO lies around 5–10%. 
Table 3. General protocol for DCC and protocol for DCC coupled to 1H-STD-NMR. * 
Aniline or another nucleophilic catalyst could be added when required. ** In a control 
experiment, no protein is added. *** Buffer conditions to guarantee protein stability 
should be determined a priori. 
 Final concentration in general DCC 
Final concentration used in DCC coupled 
to 1H-STD-NMR[24] 
Aldehyde 0.1 mM 0.4 mM 
Hydrazide 0.1–0.3 mM 1 mM (for each of the five hydrazides) 
DMSO 5–10^% 5–10^% 
Aniline* 10 mM – 
Protein** 10–100 µM 4 µM 
Buffer*** 0.1 M Ammonium acetate in D2O (0.1 M, pH 4.6) 






Control experiments should be considered, which should clarify where binding of 
molecules to the protein occurs and if it is specific or unspecific. This could for 
example be performed by the addition of a known inhibitor. If the previously 
observed amplification is not observed any longer, then the hit compounds are 
competitive binders. Based on the work of Danieli et al., B. Ernst and coworkers 
propose that the use of bovine serum albumin (BSA), as a negative control 
template for which no amplification is expected since the binding pocket is 
different, is not a good control since it could influence the library composition, 
whilst the use of a competitive inhibitor is better. BSA has been used in DCC to 
show that the applied library only gives hits with the real target and that BSA 
would yield the same result as the blank.[21,57] BSA is commonly known for its 
stability and was thought not to interfere with biological reactions, however 
recently DCC experiments have even been used to target BSA.[58] 
1.3.2 Analysis of the DCLs 
Different techniques such as fluorescence-polarization, SPR, ITC, MST, STD-
NMR, crystallography and others can be used to evaluate and possibly optimise 
obtained hits. We and Rademann and coworkers have reviewed the analytical 
methods used in protein-templated dynamic combinatorial chemistry to detect 
hit compounds. [23][59]  
A commonly applied method to analyse DCC experiments is the recording of 
HPLC-MS chromatograms of the libraries. As an illustrative example of the 
comparative approach, we drew HPLC chromatograms of a blank library and a 
target library (Figure 5). When we compare both chromatograms, we see that 
peak number five has increased in the library containing the target, whereas 
peaks three and six have decreased. The total amount of building blocks stays the 
same, only the equilibrium can be shifted towards one or more products. 
In order to accurately determine the amplification or decrease of peaks, their 
relative peak areas (RPA) should be compared. The fictional RPAs of both 
chromatograms in Figure 5 are given in Table 4. The amplification factor in 
percentage can be calculated by equation 1, where the amplification factor in ‘fold’ 
is given by equation 2. Using these two equations, the product at peak five has 
increased by 100% or twofold. Frei et al. report on a particularly thorough 
analysis of a DCL using the lectin FimH as a target, using HPLC analysis with an 
optimised DCC protocol.[36] 
Equation 1: amplification factor (%) = 
𝑅𝑃𝐴𝑡𝑎𝑟𝑔𝑒𝑡–𝑅𝑃𝐴𝑏𝑙𝑎𝑛𝑘
𝑅𝑃𝐴𝑏𝑙𝑎𝑛𝑘
∗ 100%  














Figure 5. Schematic example of HPLC chromatograms: a) blank library chromatogram, 
b) target library chromatogram. 





area in blank (%) 
Relative peak 





in ‘fold’  
1 10 10 - 1 
2 15 15 - 1 
3 20 16 –20% 0.8 
4 16 16 - 1 
5 12 24 100% 2 
6 27 19 –30% 0.7 
Total 100% 100%   
1.3.3 DCL analysed with STD-NMR spectroscopy 
Inspired by the work of Ramström and coworkers[20], we analysed the formed 
DCLs by STD-NMR spectroscopy (Scheme 3). We used the model enzyme 
endothiapepsin as target. As a control with a known binder we used saquinavir 
(Ki = 48 nM), a potent peptidic inhibitor, to differentiate specific from nonspecific 
binding. Each sub-library contained all five hydrazides and one of the aldehyde 
building blocks and was allowed to equilibrate for 24 hours before adding the 
target. By analysing the imine-type proton signals of the acylhydrazone products 
in the 1H-STD-NMR spectra (Figure 6) we identified in total eight binders. To 
confirm the results from STD-NMR, we performed an enzyme-inhibition assay 
and showed that the hits were inhibitors with IC50 values ranging from 12.8 µM to 
365 µM. The high hit rate in this publication is due to use of five sublibraries 
detecting the best binder of each library, whereas in a regular ptDCC setup only 




result of the synergistic combination of de novo structure based drug design 
(SBDD) and DCC. In STD-NMR the protein is used as a tool to analyse the library, 






Scheme 3. Formation of dynamic combinatorial library and enzymatic selection of the 















Figure 6. DCL generated from H1–5 + A4: (aromatic region) a) 1H-STD-NMR spectrum 
of H1–5 + A4, b) 1H-NMR spectrum of H1–5 + A4, c) 1H-NMR spectrum of H3+A4, 
d) 1H-NMR spectrum of H4+A4 (2 singlets correspond to the E/Z isomers), e) H1+A4, f) 
H2+H4 and g) H5+A4. Figure was adapted from Mondal et al.[24] 
1.3.4 How to proceed after obtaining hits 
Having obtained a validated hit, identified by de novo structure-based drug 
design in combination with DCC and STD-NMR, we have used a structure-based 
design approach to improve the molecular recognition by the target.[60] In this 
specific case, we were fortunate to have an x-ray crystal structure of the target 
endothiapepsin in complex with the hit. If this is not the case, optimization is still 
possible, relying on structure–activity relationships. 
1.4 DCC in a synergistic combination with fragment 
linking 
For fragment linking, two or more fragments have to bind to different but 
adjacent sites of the enzyme active site.[61] This approach introduces one 
additional component into the ligand system: a linker moiety. Finding the right 
linker motif, whilst maintaining the binding poses of both fragments, which 
orients the individual fragment units in the favourable geometry in relation to 
each other without introducing too much flexibility, can be challenging. The 
combination of two fragments with rather low affinity could result in significantly 
higher affinity and has the potential to result in ‘superadditive’ contributions of 
both binding motifs. The challenge in fragment linking is the exploration of the 
binding mode of both fragments and the identification of an optimal linker fitting 











translates into synergistically improved affinity. By binding of a fragment to a 
target protein, rotational and translational entropy is lost. This entropy penalty 
has to be overcompensated by attractive interactions formed between the ligand 
and the target. When two fragments bind in parallel to adjacent sites, each has to 
pay this entropy penalty. When these two fragments are linked together in an 
ideal way, the resulting singular compound only encounters the loss of rigid body 
entropy once. Hence, the observed affinity will be much greater than only the sum 
of the individual affinities.[62] The additional binding energy gained, is often also 
referred to as linker energy. To overcome the challenges associated with fragment 
linking, we pioneered a synergistic combination with DCC. For this proof-of-
concept study, we again used the model enzyme endothiapepsin.[35] X-ray crystal 
structures of endothiapepsin in complex with fragment inhibitors 1 and 2 (PDB 
IDs: 4KUP and 3T7P) identified by DCC were used as a starting point for fragment 
linking studies facilitated by DCC. Hits 1 and 2 display IC50 values of 12.8 µM and 
14.5 µM and LEs of 0.27 and 0.29, respectively. The linking of 1 and 2 should 
generate an inhibitor that occupies two binding pockets of endothiapepsin 
(Figure 7). 
 
Figure 7. Structures of hits 1 and 2 and linked bisacylhydrazone linked inhibitors 3 and 
4.[35] 
The homo-bis-acylhydrazones 3 and 4 were hits from the DCC experiments and 
were synthesised and evaluated accordingly. Compared to compound 2, the 
potency of inhibitor 3 was increased 240-fold, yielding an IC50 value of 0.054 µM 
and a LE value of 0.29. For inhibitor 4 an IC50 of 2.1 µM and a LE value of 0.25 
was determined (Figure 7).[35] Obviously, only the symmetric linking modality 






There are a number of steps which should be carefully taken into account, in order 
to obtain active hits by DCC. If information on the target is available, e.g. a crystal-
structure, one could consider a structure-based design when choosing the 
building blocks. The type of reversible linkage to be used can be chosen at this 
stage. Conditions necessary for the equilibration to take place should be 
compatible with the target. After establishing conditions, which will ensure the 
target remains folded, the actual DCC experiment can be started. To do so, stock 
solutions of building blocks, catalyst and protein should be prepared. The formed 
DCLs can be analysed by different techniques such as STD-NMR or HPLC-MS. 
Compounds that have been selected by the target, and their biochemical 
properties should be evaluated and possibly optimised in further studies. 
1.6 Outline of this thesis 
Dynamic combinatorial chemistry (DCC) has evolved over the past decades from 
a tool to easily generate a pool of derivatives to an efficient technique to find hit 
compounds when applied on a target. To be able to use target-directed DCC 
(tdDCC), a number of criteria must be met ranging from biocompatibility, 
solubility, stability, pH dependence to temperature and type of reversible 
reaction.  
The protein family of 14-3-3 has been selected as a target, since it allows for all of 
these criteria to be met. 14-3-3 proteins are involved in protein-protein 
interactions (PPIs) in many different biological processes, ranging from diseases 
to cell-cycle control and signal transduction. Modulating 14-3-3 proteins for 
binding is therefore an important class of research.  
The first aim of this thesis is applying DCC on biological relevant targets; such as 
14-3-3 proteins and glucansucrases. The second aim of this thesis is on extending 
the list of reversible reactions, which can be applied in tdDCC. This allows 
medicinal chemists more freedom, by being able to use different scaffolds. 
Therefore, the overall objective is to find new applications of DCC to medicinal 
chemistry. 
In chapter 3, we apply tdDCC on the 14-3-3ζ isoform. We use the PPI complex of 
14-3-3ζ/synaptopodin in acylhydrazone-based DCC, aiming to find small drug-
like molecules which can stabilise this PPI.  
Chapter 4 describes the application of tdDCC on a glucantransferase, which is 
found to be causative for adhesion of bacteria to the tooth enamel, which can lead 




Finally, in chapters 5 and 6 the design and first applications of new scaffolds for 
tdDCC is described. In chapter 5, the application of nitrone-based DCC with 
endothiapepsin is evaluated. And in chapter 6, the thiazolidine scaffold is 
investigated and DCC conditions optimised for endothiapepsin.  
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